Oncology

Primary peritoneal carcinoma

ORPHA:168829 ↗Gene BRCA1

Search all Primary peritoneal carcinoma trialsAlert me when a trial opens

studies recruiting now

as of 7 Sept 2026

841

studies registered in total

as of 7 Sept 2026

countries with a recruiting site

as of 7 Sept 2026

24 Mar 2025

most recent study posted

among recruiting studies

Recruiting trials

RecruitingPhase 3NCT06824467

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Sponsor Merck Sharp & Dohme LLCWhere United States, Argentina, Australia +26 (196 sites)Studying Sacituzumab tirumotecan, BevacizumabUpdated 3 Sept 2026

See details

RecruitingPhase 2NCT05564377

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Sponsor National Cancer Institute (NCI)Where United States, Puerto Rico (482 sites)Studying Alpelisib, BinimetinibUpdated 3 Sept 2026

See details

RecruitingPhase 2NCT06890338

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Sponsor AbbVieWhere United States (69 sites)Studying Carboplatin, Mirvetuximab SoravtansineUpdated 1 Sept 2026

See details

RecruitingPhase 2NCT06492070

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Sponsor Emory UniversityWhere United States (3 sites)Studying Best Practice, CilostazolUpdated 27 Aug 2026

See details

RecruitingPhase 3NCT05281471

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Sponsor Genelux CorporationWhere United States (33 sites)Studying olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatinUpdated 26 Aug 2026

See details

Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.

See all 82 recruiting studies

Where recruiting studies are running

Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.

Keep watching

Get an email when a new Primary peritoneal carcinoma study opens.

One email a day at most. Unsubscribe with one click.

Used only for these alerts. Privacy.

Support

Patient organisations

We do not yet list a dedicated organisation for this condition. The directories below are the best route.

NORD ↗GARD ↗Orphanet ORPHA:168829 ↗

About Primary peritoneal carcinoma

RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the gene involved (BRCA1).

Orphanet expert page ↗GARD (NIH) ↗

Related conditions

Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).